$AVR

L1 Capital Pty Ltd sold $3.6M of AVR (indirect holdings)

L1 Capital Pty Ltd sold 441,548 indirectly-held shares of Anteris Technologies Global Corp. (AVR) at an average of $8.14 ($8.09–$8.19, $3.60M total) across 2 trades over 2026-07-27 to 2026-07-28.

Original reporting
SEC EDGAR · L1 Capital Pty Ltd
Published Jul 29, 2026, 10:40 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 29, 2026, 11:10 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AVR
Neutral
medium confidence
Mentioned
$AVR
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AVRNeutralLow
01

Why it matters

A 10% owner’s indirect open-market sale of about $3.6M is disclosed, but the filing provides no new operational, regulatory, or financial guidance for AVR.

02

Market read

Traders may monitor for follow-on selling or changes in ownership, but this disclosure alone is unlikely to drive a durable repricing.

03

What to watch

Indirect holdings and the lack of a stated reason for the sale make it hard to infer conviction; the sale window spans two days and may reflect pre-planned liquidity needs.

Relevance 6/10Novelty 4/10Timing: filed 2026-07-29, covering sales on 2026-07-27 to 2026-07-28

Background

The article is an SEC Form 4 insider transaction disclosure for Anteris Technologies Global Corp. (AVR).

Company-level read

Ticker impact

$AVRNeutralMedium confidence
Context

L1 Capital Pty Ltd, a 10% owner, sold 441,548 AVR shares in open-market trades for about $3.6M at $8.09 to $8.19.

Expected impact

Near-term impact likely muted; any move would be more about broader tape/liquidity than this single Form 4.

Evidence & confidence

The filing is a Form 4 open-market sale with no 10b5-1 plan and no accompanying company-specific news, so it is typically interpreted as diversification rather than a new catalyst.

Market effects

No clear sector read-through from a single insider sale filing.

No regional impact indicated.

No global market relevance indicated.

Counterpoint

Absence of a 10b5-1 plan could be read as more discretionary selling, which some traders may interpret as bearish near-term sentiment.

Key entities

  • Anteris Technologies Global Corp.

    Subject of the Form 4 insider transaction disclosure (AVR).

  • L1 Capital Pty Ltd

    Reported indirect open-market sale of AVR shares totaling about $3.6M.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AVRMedAI 8/10

Small Cap watch: ASX small caps ease after strong week as NewPeak, Orthocell and Anteris advance drilling, sales and data

The S&P/ASX Small Ordinaries Index fell 0.74% on Friday but gained 3.03% over the week. NewPeak Metals completed drilling in Argentina, Orthocell reported record US sales, and Anteris Technologies released positive heart valve data. NewPeak tested gold mineralization, Orthocell sold 92 units of Remplir, and Anteris' valve showed improved haemodynamics in 22 patients.

$AVRMedAI 8/10

Anteris Reports Medium-Size DurAVR THV Outcomes from the EMBARK Study at TCT 2026

Anteris Technologies (NASDAQ: AVR, ASX: AVR) reported 30-day outcomes for its DurAVR THV in 22 patients with medium aortic annuli, showing positive hemodynamic and safety results. The DurAVR THV is being evaluated in the ongoing PARADIGM trial, a global study comparing it to commercially available TAVRs. The company aims to confirm the valve's effectiveness in a randomized setting.

$AVRMedAI 8/10

Anteris Technologies secures German clearance to expand PARADIGM heart valve trial

Anteris Technologies (ASX:AVR, NASDAQ:AVR) received German regulatory approval to expand its PARADIGM heart valve trial, allowing patient recruitment in Europe's largest market. The trial aims to enroll 1,000 patients to evaluate the DurAVR valve against existing devices. The company expects Germany's expertise to accelerate enrollment. DurAVR is a transcatheter heart valve designed to mimic a healthy aortic valve.